Toku Inc. announced last week it received US Food and Drug Administration breakthrough device designation for its MyKidneyAI technology, which uses AI to analyze retinal images at routine eye exams to detect elevated chronic kidney disease risk in people with diabetes.
Most people with diabetes are not routinely screened for CKD, resulting in disease not being detected until it has developed to an advanced
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?